Metropolis Healthcare Limited (METROPOLIS) Fair Value & Analysis
Healthcare · IN · Market cap ₹113B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +3.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹410.75 – ₹546.00 · fair‑value band ₹151.22 – ₹252.03 · the ₹544.30 price screens above the ₹201.63 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Metropolis Healthcare Limited (METROPOLIS) currently trades at ₹544.30, while our model-based Fair Value estimate is ₹201.63 — implying the stock looks roughly 63.0% overvalued today. We read business quality at 72/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Metropolis Healthcare Limited generated revenue of ₹16.5B at a net margin of 11.6%. Revenue grew 23.0% year over year. It earns a return on equity of 13.4%. Net debt stands at ₹1.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Metropolis Healthcare Limited reported revenue of ₹16.5B in FY2026 versus ₹12.3B in FY2022, a compound +7.6%/yr. Reported net income was ₹1.9B in FY2026, compounding −2.9%/yr from FY2022.
Is METROPOLIS fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $472.80 | $190.31 | -60% |
| Danaher Corporation DHR | $186.64 | $85.95 | -54% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Metropolis Healthcare Limited (METROPOLIS) undervalued?
What is the fair value of METROPOLIS?
What is the quality score of METROPOLIS?
What is the revenue of Metropolis Healthcare Limited (METROPOLIS)?
What is the net profit margin of METROPOLIS?
Does Metropolis Healthcare Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.